Adrecizumab (HAM8101) to Improve Prognosis and Outcomes in COVID-19 Trial (AGNES-19)

Universitätsklinikum Hamburg-Eppendorf

Status and phase: Terminated; Phase 2

Conditions: COVID-19

Treatments: Biological: Adrecizumab (HAM 8101); Drug: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT05156671

AGNES-19

Details and patient eligibility

About

The clinical trial is designed as a prospective, multi-center, double-blind, randomised, placebo-controlled, interventional trial to assess safety, tolerability and efficacy of Adrecizumab (on top of SOC) in patients with COVID-19, and to evaluate if improvement of vascular integrity with Adrecizumab on top of SOC is superior to placebo/ control substance (NaCl 0.9%) on top of SOC in reduction of morbidity and mortality endpoints in patients with COVID-19.

The main reason for admission to ICU and need for mechanical ventilation of these patients is acute lung injury within a broad pneumonic spectrum, increased ventricular filling pressures and resulting congestion. It is hypothesized, that Adrenomedullin (ADM) is a key player in the (dys)-regulation of vascular integrity (Figure 2). Adrecizumab is the first-in-class humanized monoclonal anti-Adrenomedullin antibody, and acts as a long-lasting plasma Adrenomedullin enhancer stabilizing barrier function at a reasonable safety profile. The mode of action for the anti-Adrenomedullin antibody Adrecizumab has been developed on the basis of published data, own experimental data and theoretical considerations.

Enrollment: 16 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Hospitalization with moderate to severe COVID-19, defined as fulfilling at a minimum the following clinical status category on the WHO 8-point ordinal scale: (i) "score 4" [oxygen via mask or nasal]
• Laboratory-confirmed SARS-CoV-2 infection at index hospitalisation as determined by PCR or other validated commercial or public health assay
• Bio-ADM ≥50 pg/mL or ≥30% increase until the end of the next day (with a minimum of 35 pg/mL at all)
• DPP3 ≤30 ng/mL
• Age ≥18 years at time of screening
• Body weight ≤ 150 kg at time of screening

Exclusion criteria

• Life expectancy less than 3 months before COVID-19 at the discretion of the Investigator
• Invasive mechanical ventilation ≥ 72 hours at time-point of randomization
• Resuscitation > 45 minutes
• Hypersensitivity to the active substance, to Adrecizumab or any of its excipients, or known serious hypersensitivity to other monoclonal antibodies
• Uncontrolled haematological/ oncological malignancies
• Pre-existing severe chronic liver disease (i.e. Child-Pugh C) before COVID-19 hospitalization
• Absolute neutropenia <500 per μL

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

16 participants in 2 patient groups, including a placebo group

Adrecizumab (HAM 8101)

Experimental group

Description:

Adrecizumab (HAM 8101) on top of standard of care. Adrecizumab (HAM8101) is a humanized IgG1 monoclonal antibody (mAb). 2 mg/kg body weight Adrecizumab diluted in up to 100 mL saline as single dose infusion.

Treatment:

Biological: Adrecizumab (HAM 8101)

Placebo/ control substance (NaCl 0.9%)

Placebo Comparator group

Description:

100 mL saline as single dose infusion

Treatment:

Drug: Placebo